Cystatin C may serve as a suitable blood-based biomarker to monitor renal functional decline in patients scheduled for peptide receptor radionuclide therapy

#3612

Introduction: Peptide receptor radionuclide therapy (PRRT) for treating somatostatin receptor (SSTR)-positive tumors may be associated with nephrotoxicity.

Aim(s): To find suitable laboratory-based biomarkers for assessing renal function loss in a longitudinal setting under PRRT.

Materials and methods: In 40 patients, which received 4 cycles of PRRT, we recorded laboratory-based renal function parameters, including creatinine (mg/dl), glomerular filtration rate (eGFR based on the chronic kidney disease epidemiology collaboration, ml/min/1.73qm) and cystatin C (mg/dl). We then compared those laboratory values with the tubular extraction rate (TER) derived from renal scintigraphy (serving as reference) at baseline and longitudinally.

Conference:

Presenting Author: Hasenauer N

Authors: Hasenauer N, Hartrampf P, Weich A, Higuchi T, Schirbel A,

Keywords: sstr, theragnostics, prrt, renal, nephrotoxicity,